Whole breast ultrafractionation radiotherapy after breast-conserving surgery in early breast cancer: A single-center, prospective, observational study from China

Abstract

Objective: This single-center, prospective, observational study was designed to investigate the toxicities, patient-reported outcome (PRO), and dosimetric analysis of whole breast ultrafractionation radiotherapy (RT) after breast-conserving surgery (BCS) in early breast cancer (BC).

Patients and methods: Patients diagnosed with BC stage I, II and treated with BCS were enrolled. A dose of 26 Gray (Gy) in five fractions was prescribed to the whole breast and tumor bed. Clinical endpoints included toxicities, PRO, and dosimetric analysis. PRO was measured by the European Organization for Research and Treatment of Cancer general quality of life questionnaire (EORTC QLQ-C30) and the BC-specific questionnaire (EORTC QLQ-BR23) questionnaires.

Results: Between January 2022 and June 2023, 62 female patients were enrolled. The median age was 45 years. Most patients (83.9%) were diagnosed with pathological stage I disease. The median planning target volume (PTV) was 456.4 mL. The minimum, maximum, and mean doses, and D₉₅ (dose of PTV irradiated volume more than 95%) to PTV were 20.2, 28.8, 27.2, and 26.3 Gy, respectively. The median mean lung dose and percentage lung volume receiving 8 Gy (V₈) were 3.6 Gy and 13.4%, respectively. The median mean heart dose, V_1.5 (percentage of organ volume irradiated with 1.5 Gy or higher), and V₇ (percentage of organ volume irradiated with 7 Gy or higher) were 0.6 Gy, 6.8%, and 0.4%, respectively. Cosmetic effects before RT showed no obvious differences compared to that post RT. No toxicities of grade 3 or higher occurred. Five patients had asymptomatic radiation pneumonia (grade 1), and 12 patients had radiation dermatitis (grade 1). No factor was significantly related to radiation dermatitis or radiation pneumonia. For the EORTC QLQ-C30 and QLQ-BR23 questionnaires, all function and symptom scores before RT had no significant differences compared with that after RT, 1–2 months after RT, and 3–4 months after RT. Ultrafractionation RT did not worsen PRO. The 1-year crude local control was 100%.

Conclusion: Whole breast ultrafractionation RT after BCS in early BC has no severe toxicities and does not affect PRO. These results need to be further validated with a longer follow-up and a larger sample size.

Keywords

ultrafractionation radiotherapy / breast cancer / breast-conserving surgery / toxicities / patient-reported outcome

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2] Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med. 1995;333(22):1444-1456.

[3] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.

[4] Wang SL, Fang H, Hu C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China. J Clin Oncol. 2020;38(31):3604-3614.

[5] Group ST, Bentzen SM, Agrawal RK, et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331-341.

[6] Group ST, Bentzen SM, Agrawal RK, et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098-1107.

[7] Shaitelman SF, Lei X, Thompson A, et al. Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a randomized, noninferiority clinical trial. J Clin Oncol. 2018;36(35):3495-3503.

[8] Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613-1626.

[9] Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21-e31.

[10] Karsten MM, Roehle R, Albers S, et al. Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients. Eur J Cancer. 2022;163:128-139.

[11] Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756-2768.

[12] Mierzynska J, Taye M, Pe M, et al. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer. 2020;125:69-82.

[13] Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1979;5(2):257-261.

[14] Curigliano G, Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM. Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer. Oncologist. 2019;24(11):e1034-e1043.

[15] Omarini C, Thanopoulou E, Johnston SR. Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat. 2014;146(2):245-258.

[16] Mo H, Jazieh KA, Brinzevich D, Abraham J. A review of treatment-induced pulmonary toxicity in breast cancer. Clin Breast Cancer. 2022;22(1):1-9.

[17] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998.

[18] van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35(11):1171-1178.

[19] Karlsen J, Tandstad T, Sowa P, et al. Pneumonitis and fibrosis after breast cancer radiotherapy: occurrence and treatment-related predictors. Acta Oncol. 2021;60(12):1651-1658.

[20] Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814-822.

[21] Nugent K, Quinlan E, Cleary S, et al. Implementation of 26 Gy in five fractions over 1 week adjuvant radiotherapy for breast cancer: prospective report of acute skin toxicity and consideration of resource implications. Breast. 2023;67:55-61.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.